Still, as assessed in the Prospective Comparison of angiotensin receptor–neprilysin inhibitor with ARB Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial, the use of sacubitril/valsartan missed the composite primary endpoint of reducing hospitalization and death in HFpEF [93]. The gene discussed is MME; the disease is hydrops fetalis.